York Pharma Share Discussion Threads

[kiki14p] 02/5/2008 06:26

Nobbygnome - wishful thinking or have you heard any rumours?

[nobbygnome] 01/5/2008 22:53

I feel an approval coming on.......

[wetdream] 01/5/2008 09:59

Hmm....
YRK emerging from its cryogenic state?

[wetdream] 29/4/2008 08:33

Shows you can't get it right every time.

[m4p] 28/4/2008 19:37

Nigel Wray paid £1.40 plus

Up she goes again

[m4p] 28/4/2008 19:36

Nigel Wray paid £1.40 plus

Up she goes again

[m4p] 28/4/2008 19:36

Nigel Wray paid £1.40 plus

Up she goes again

[ch1ck] 25/4/2008 07:54

M4P what the hell is that based on?

[m4p] 21/4/2008 21:35

Up she goes :-)

[roorontev] 17/4/2008 07:53

Avoid,this company's record is appalling when it comes to Date lines,any long term holders have been badly let down...IMHO...

PS...Beware of the friendly Ramper here too....;-(

[bioshark] 16/4/2008 17:08

>> expected by September
in what year?
LOL

[wetdream] 11/4/2008 00:17

How on earth can they say 'by September' with any confidence?
The EMEA/MHRA are laws unto themselves, and are in their own bureaucratic world.

[topvest] 10/4/2008 21:35

A decision on approval from UK regulators is expected by September.

....blimey another 6m!

[m4p] 10/4/2008 21:16

Nobbynome

Your time has arrived for a long awaited comeback

[ch1ck] 10/4/2008 20:15

Is this this the turn around we have been waiting for? well a rise of 9% today was a step in the right direction.

[wetdream] 10/4/2008 15:59

'York shares,... are down from last year's high of 215p'
??????????????
Good old journalists - always check their facts!

[ch1ck] 10/4/2008 09:52

Handy

Nice post

Got the rocket boots on this one is about to fly

[handycam] 10/4/2008 08:59

Today's Times:


York Pharma

Big pharmaceutical companies are the obvious safe haven for investors in times of economic stress, but York Pharma, the dermatological research minnow, offered a glimpse yesterday of the potential rewards on offer for investing in recession-proof disease sectors provided they have the stomach for a bumpy ride.

York Pharma's main UK money-spinner is Zindaclin, an acne treatment bought last December. The spot curer is popular with UK doctors and first-half revenues to the end of March will be ahead of City expectations, the company confirmed yesterday. US approval for Zindaclin is hoped for next year but a launch will require a tie-up with a large domestic sales force. Abasol, a treatment for fungal skin infections, is the next potential big seller in the pipeline. A decision on approval from UK regulators is expected by September. Cash reserves totalled £4.7 million in September, which, with revenues from Zindaclin, should see York through to a launch next year of Abasol. York shares, up 3¾p to 47½p yesterday, are down from last year's high of 215p. Hold on.

[ch1ck] 09/4/2008 15:35

Just for your infomation I bought two lots of shares today in YRK and both showed up as sells the last one was a few mins ago so I would take the traded buy sell figures with a pinch of salt.

cheers All

[intrinsicinvestor] 09/4/2008 14:34

As I've mentioned before, I'm looking for evidence that new businesses can make some decent profits, even if for 2009. This will ultimately provide support. In the current bear market for small caps, new buyers will want to see earnings first. IMHO

[lqs] 09/4/2008 13:31

A lot of money raised quite recently at 3 times this share price though. How did they manage that?

[topvest] 09/4/2008 07:56

Well, could have been worse. At least the new products are doing well. Still waiting for Abasol though!!

[ursamajorra] 09/4/2008 07:49

RNS Number:9370R
York Pharma plc
09 April 2008

York Pharma plc

('York Pharma' or 'the Company')

Date of interim results and trading update


Hitchin, UK, 9 April 2008 York Pharma, the AIM-listed (AIM:YRK) strategic
acquirer, developer and marketer of pharmaceutical products in the field of
dermatology, today confirms that it will announce its interim results for the
half year ended 31 March 2008 on 28 May 2008 and provides an update on trading.
This will be the first occasion that York Pharma's results will have been
prepared under the recently introduced International Financial Reporting
Standards ("IFRS").

Revenues for the period, including the contribution from Derms Development's
products, which were acquired towards the end of 2007, are anticipated to be
ahead of expectations as a result of strong growth in sales of all marketed
products, notably Zindaclin(TM), a treatment for mild to moderate acne. In
addition, York Pharma's pipeline of innovative products continues to progress
through its various stages of development.

Commenting on the update, Terry Sadler, CEO of York Pharma, said: "The
integration of Derms Development has progressed well and we are now seeing the
benefits of selling the brands through York's sales and distribution
infrastructure in Europe. The roll-out of our business model continues to take
shape as we build a specialist dermatology business with strongly growing
marketed products and a pipeline with high growth potential in all stages of
development from pre-clinical through to Abasol(TM), which awaits its first
regulatory approval."